By Jeff Overley (February 8, 2013, 2:23 PM EST) -- Shire LLC will pay $48 million to settle allegations in New York federal court that it shorted Impax Laboratories Inc. on supplies of a generic version of increasingly popular attention deficit hyperactivity disorder drug Adderall XR, the companies announced Friday.
As part of the deal, the drugmakers entered into an amended licensing agreement that runs through September 2014 and calls for California-based Impax to pay a share of profits from Adderall sales to U.K.-based Shire. The settlement comes more than two years after Impax sued Shire, manufacturer of brand-name Adderall, for allegedly "supplying only a small fraction of Impax's orders" despite...
Stay ahead of the curve
In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.
Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
Create custom alerts for specific article and case topics and so much more!